Treatment of benign prostatic hyperplasia with 5-α-reductase inhibitor: Morphological changes in patients who fail to respond

Journal of Clinical Pathology

Volumn 49, Issue 4, 1996, Pages 324-328

  Montironi, R ^a   Valli, M ^a   Fabris, G ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

5 reductase; Benign prostatic hyperplasia; Clear cell papillary; Finasteride; Hyperplasia; Postatrophic hyperplasia

Indexed keywords

FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATECTOMY;

EID: 0029923604     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.49.4.324     Document Type: Article

References (22)

1. McNeal JE. The pathobiology of nodular hyperplasia. In: Bostwick DG, ed. Pathology of the prostate. New York: Churchill Livingstone, 1990:31-6.
2. Isaacs JY. Etiology of benign prostatic hyperplasia. Eur Urol 1994;25(Suppl):6-9.
3. The Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993; 22:291-9.
4. Imperato-McGinley J. 5α-reductase deficiency: human and animal models. Eur Urol 1994;25(Suppl):20-3.
5. Tewari A, Shinohara K, Narayan P. Transition zone volume and transition zone ratio: predictor of uroflow response to finasteride therapy in benign prostatic hyperplasia patients. Urology 1995;45:258-65.
6. Gormley GJ, Stoner E, Bruskewitz RC and the Finasteride Study Group Members. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992; 327:1185-91.
7. Peter CA, Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med 1987;317:599-604.
8. Cohen SM, Werrmann JG, Rasmusson GH, Tanaka WK, Malatesta PF, Prahalada S, et al. Comparison of the effects of new specific azasteroid inhibitors of steroid 5α-reductase on canine hyperplastic prostate: suppression of prostatic DHT correlated with prostate regression. Prostate 1995; 26:55-71.
9. Juniewicz PE, Hoekstra SJ, Lemp BM, Barbolt TA, Devin JA, Gauthier E, et al. Effect of combination treatment with zanoterone (WIN 49596), a steroidal androgen receptor antagonist, and finasteride (MK-906), a steroidal 5-reductase inhibitor, on the prostate and testes of beagle dogs. Endocrinology 1993;133:904-13.
10. Prahalada S, Keenan KP, Hertzog PR, Gordon LR, Peter CP, Soper KA, et al. Qualitative and quantitative evaluation of prostatic histomorphology in rats following chronic treatment with finasteride, a 5-alpha reductase inhibitor. Urology 1994;43:680-5.
11. Montironi R, Magi Galluzzi C, Scarpelli M, Diamanti L. Quantitative characterisation of the frequency and location of cell proliferation and death in prostate pathology. J Cell Biochem 1994;19(Suppl):238-45.
12. Montironi R, Magi Galluzzi C, Muzzonigro G, Prete E, Polito M, Fabris G. Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate, prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J Clin Pathol 1994;47:906-13.
13. Montironi R, Muzzonigro G, Magi Galluzzi C, Giannulis I, Diamanti L, Polito M. Effect of LHRH agonist and flutamide (combination endocrine therapy) on the frequency and location of proliferating cell nuclear antigen and apoptotic bodies in benign prostatic hyperplasia. J Urol Pathol 1994;2:161-71.
14. Bologna M, Muzi P, Biordi L, Festuccia C, Vicentini C. Finasteride dose-dependently reduces the proliferation rate of the LnCap human prostatic cancer line in vitro. Prostate 1995;45:282-90.
15. Russo P, Warner JA, Perez G, Heston WDW. TRPM-2 gene expression in normal rat ventral prostate following castration and exposure to diethylstilbestrol, flutamide, MK-906 (finasteride), and Coumarin. Prostate 1994;24: 237-43.
16. Tuttle RM, Loop S, Jones RE, Meikle AW, Ostenson RC, Plymate SR. Effect of 5-α-reductase inhibition and dexamethasone administration on the growth characteristics and intratumor androgen levels of the human prostate cancer cell line PC-3. Prostate 1994;24:229-36.
17. Lamb JC, English H, Levandoski PL, Rhodes GR, Johnson RK, Isaacs JT. Prostatic involution in rats induced by a novel 5α-reductase inhibitor, SK&F 105657: role for testosterone in the androgenic response. Endocrinology 1992;130:685-94.
18. Cheville JC, Bostwick DG. Postatrophic hyperplasia of the prostate. A histologic mimic of prostatic adenocarcinoma. Am J Surg Pathol 1995;19:1068-76.
19. Bainborough AR. Squamous metaplasia of the prostate following estrogen therapy. J Urol 1952;68:329-36.
20. Ayala AG, Srigley JR, Ro JY, Abdul-Karim FW, Johnson DE. Clear cell cribriform hyperplasia of prostate: report of 10 cases. Am J Surg Pathol 1986;10:665-71.
21. Shapiro E, Hartanto V, Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate 1992;21:297-307.
22. Miller PD, Brewster S, Reynard J, Kirby RS. Prostatic morphometry following treatment with finasteride (abstract). J Urol 1993;149:423A.